Activation of the ERBB/HER family of proteins has been repeatedly implicated in oncogenesis and can be induced by various molecular alterations, including EGFR point mutations or short insertions or deletions (indels) in NSCLC and ERBB2 amplification in breast cancer (10, 11). Here, ERBB2 is linked to breast carcinoma.